Combating Streptococcus agalactiae infections by designing a multi-epitope vaccine using molecular dynamic...

Area of Science:

• Vaccinology
• Immunoinformatics
• Computational Biology

Background:

• Streptococcus agalactiae (Group B Streptococcus) causes severe infections in neonates and vulnerable populations.
• There is a critical need for effective vaccines against GBS due to high rates of newborn mortality and stillbirths.
• No licensed vaccine currently exists for GBS meningitis.

Purpose of the Study:

• To construct a multi-epitope vaccine (MEV) targeting virulent proteins of Streptococcus agalactiae strain 2603 V/R.
• To identify antigenic proteins and their corresponding B and T cell epitopes.
• To validate the designed MEV using molecular docking and dynamic simulation studies.

Main Methods:

• Proteomic analysis of Streptococcus agalactiae strain 2603 V/R to identify antigenic proteins.
• B and T cell epitope prediction using reverse vaccinology tools and immunoinformatics.
• Construction of an MEV, followed by molecular docking and dynamic simulations for validation.

Main Results:

• Four target proteins yielded 27 predicted epitopes for MEV construction.
• Docking analysis revealed significant binding energies with Toll-like receptor (TLR), MHC I, and MHC II.
• Molecular dynamic simulations confirmed the stability of the vaccine complex with immune receptors.

Conclusions:

• Virulent proteins of Streptococcus agalactiae offer promising targets for an effective MEV.
• The developed MEV construct demonstrates potential for inducing specific and lasting immunity.
• This research paves the way for a new preventive strategy against Streptococcus agalactiae infections.